Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Richard Adcock Biography and Net Worth

CEO of ImmunityBio

Richard (Rich) Adcock was named Chief Executive Officer of ImmunityBio in January 2021. Formerly CEO of NantKwest, he has held leadership positions in healthcare for nearly 30 years and is recognized for his expertise in building cultures focused on rapid, strategic innovation. He is a Six Sigma Master Black Belt, ensuring that the execution of those strategies is accompanied by strong quality systems throughout the enterprise. Previously, Adcock was CEO of Verity Health, where he led a successful restructuring event. He began his career in 1992 as a co-founder and Vice President of Research and Development for Micro Medical Systems, pioneering the development of early Cardiology Electronic Medical Records. Adcock assumed leadership roles in healthcare innovation following the company’s acquisition by GE Healthcare in 1999. He subsequently earned an MBA in Healthcare Management and joined Sanford Health where he served as President and later as Chief Innovation Officer.

How old is Richard Adcock?: Mr. Adcock is currently 55 years old. There are 6 older executives and no younger executives at ImmunityBio. The oldest executive at ImmunityBio is Dr. Hans Georg Klingemann M.D., Ph.D., Chief Science Officer of Cellular, who is 74 years old. Learn More on Richard Adcock's age.
How do I contact Richard Adcock?: The corporate mailing address for Mr. Adcock and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on Richard Adcock's contact information.
Has Richard Adcock been buying or selling shares of ImmunityBio?: Richard Adcock has not been actively trading shares of ImmunityBio within the last three months. Most recently, on Friday, October 8th, Richard Adcock bought 1,930 shares of ImmunityBio stock. The stock was acquired at an average cost of $8.81 per share, with a total value of $17,003.30. Learn More on Richard Adcock's trading history.
Who are ImmunityBio's active insiders?: ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.
Are insiders buying or selling shares of ImmunityBio?: In the last year, ImmunityBio insiders bought shares 2 times. They purchased a total of 96,915 shares worth more than $268,516.25. The most recent insider tranaction occured on June, 5th when Director Michael D Blaszyk bought 71,915 shares worth more than $197,766.25. Insiders at ImmunityBio own 83.4% of the company. Learn More about insider trades at ImmunityBio.
Information on this page was last updated on 6/5/2023.

Richard Adcock Insider Trading History at ImmunityBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/8/2021	Buy	1,930	$8.81	$17,003.30

Richard Adcock Buying and Selling Activity at ImmunityBio

ImmunityBio Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Today's Range

Now: $5.11

$4.82

$5.18

50 Day Range

MA: $5.20

$3.50

$6.17

2 Week Range

Now: $5.11

$1.25

$6.93

Volume

8,384,593 shs

Average Volume

5,423,900 shs

Market Capitalization

$3.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

From Priority Gold | Ad